CN107529754A - 去乙酰氧基微管溶素h及其类似物 - Google Patents

去乙酰氧基微管溶素h及其类似物 Download PDF

Info

Publication number
CN107529754A
CN107529754A CN201680023813.XA CN201680023813A CN107529754A CN 107529754 A CN107529754 A CN 107529754A CN 201680023813 A CN201680023813 A CN 201680023813A CN 107529754 A CN107529754 A CN 107529754A
Authority
CN
China
Prior art keywords
substituted
cycloalkyl
alkylene
groups
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680023813.XA
Other languages
English (en)
Chinese (zh)
Inventor
基里亚科斯·C·尼科拉乌
迪奥尼奥斯·武卢密斯
尹军
R·伊兰德
德巴希西·曼达尔
P·克兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
William Marsh Rice University
Original Assignee
William Marsh Rice University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by William Marsh Rice University filed Critical William Marsh Rice University
Publication of CN107529754A publication Critical patent/CN107529754A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680023813.XA 2015-02-25 2016-02-25 去乙酰氧基微管溶素h及其类似物 Pending CN107529754A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562120613P 2015-02-25 2015-02-25
US62/120,613 2015-02-25
US201662275667P 2016-01-06 2016-01-06
US62/275,667 2016-01-06
PCT/US2016/019604 WO2016138288A1 (en) 2015-02-25 2016-02-25 Desacetoxytubulysin h and analogs thereof

Publications (1)

Publication Number Publication Date
CN107529754A true CN107529754A (zh) 2018-01-02

Family

ID=56789084

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680023813.XA Pending CN107529754A (zh) 2015-02-25 2016-02-25 去乙酰氧基微管溶素h及其类似物

Country Status (22)

Country Link
US (1) US10808007B2 (https=)
EP (1) EP3261443B1 (https=)
JP (1) JP2018509404A (https=)
KR (1) KR20170137725A (https=)
CN (1) CN107529754A (https=)
AU (1) AU2016222575A1 (https=)
BR (1) BR112017018305A2 (https=)
CA (1) CA2977589A1 (https=)
CL (1) CL2017002170A1 (https=)
CO (1) CO2017008600A2 (https=)
CR (1) CR20170438A (https=)
DO (1) DOP2017000202A (https=)
EA (1) EA201791896A1 (https=)
EC (1) ECSP17057131A (https=)
GT (1) GT201700190A (https=)
HK (1) HK1248069A1 (https=)
IL (1) IL254089A0 (https=)
MX (1) MX2017011024A (https=)
PE (1) PE20180355A1 (https=)
PH (1) PH12017501539A1 (https=)
SG (1) SG11201706820RA (https=)
WO (1) WO2016138288A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049140A2 (en) 2015-09-18 2017-03-23 Wake Forest University Health Sciences Angiotensin (1-7) analogs and methods relating thereto
CA2914601A1 (en) * 2015-12-11 2017-06-11 Wake Forest University Health Sciences Angiotensin-(1-7) analogs and methods relating thereto
BR112020000122A2 (pt) * 2017-07-03 2020-07-07 Glaxosmithkline Intellectual Property Development Limited derivados da n-(3-(2-(4-clorofenóxi)acetamido)biciclo[1.1.1] pentan-1-il)-2-ciclobutano-1-carboxamida e compostos relacionados como inibidores do atf4 para tratamento contra o câncer e outras doenças
CA3071024A1 (en) 2017-08-09 2019-02-14 Denali Therapeutics Inc. Compounds, compositions and methods
CN111201245B (zh) 2017-09-01 2024-04-05 戴纳立制药公司 化合物、组合物和方法
TW202428569A (zh) * 2017-09-08 2024-07-16 美商思進公司 妥布賴森(tubulysins)及其中間產物之製備方法
US11274124B2 (en) 2017-11-29 2022-03-15 William Marsh Rice University Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith
MA53765B2 (fr) 2018-12-21 2025-04-30 Regeneron Pharmaceuticals, Inc. Tubulysines et conjugués tubulysines-protéines
SG11202108552QA (en) 2019-02-13 2021-09-29 Denali Therapeutics Inc Compounds, compositions and methods
EP3924341A4 (en) 2019-02-13 2022-11-02 Denali Therapeutics Inc. Compounds, compositions and methods
TWI750728B (zh) * 2019-07-11 2021-12-21 大陸商蘇州亞盛藥業有限公司 2-吲哚啉螺環酮類化合物的製備方法及其中間體
US11694341B2 (en) 2019-12-23 2023-07-04 Texas Instmments Incorporated Cascaded architecture for disparity and motion prediction with block matching and convolutional neural network (CNN)
CN112645833A (zh) * 2021-01-29 2021-04-13 上海吉奉生物科技有限公司 一种(s)-2,6-二氨基-5-氧己酸的合成方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005327A1 (de) * 2002-07-09 2004-01-15 Morphochem Ag Komb Chemie Neue tubulysinanaloga
US20050249740A1 (en) * 2002-07-09 2005-11-10 R & D Biopharmaceuticals Gmbh Tubulysin conjugates
WO2010034724A1 (en) * 2008-09-25 2010-04-01 Universität des Saarlandes Bioactive pre-tubulysins and use thereof
US20100240701A1 (en) * 2007-10-25 2010-09-23 Endocyte, Inc. Tubulysins and processes for preparing
WO2011069116A1 (en) * 2009-12-04 2011-06-09 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
CN102725001A (zh) * 2009-08-03 2012-10-10 米德列斯公司 抗增殖化合物、其缀合物、其方法及其用途
US20130137139A1 (en) * 2010-08-06 2013-05-30 Endocyte, Inc. Processes for preparing tubulysins
WO2013149185A1 (en) * 2012-03-29 2013-10-03 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US20140227295A1 (en) * 2013-02-14 2014-08-14 Bristol-Myers Squibb Company Tubulysin compounds, methods of making and use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100047841A1 (en) * 2007-02-27 2010-02-25 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Synthesis of desacetoxytubulysin h and analogs thereof
US8980833B2 (en) * 2007-05-10 2015-03-17 R&D-Biopharmaceuticals Gmbh Tubulysine derivatives
EP2181101A2 (en) 2007-07-20 2010-05-05 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysin d analogues
IT1394860B1 (it) * 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
EP2322537A1 (en) 2009-11-12 2011-05-18 R & D Biopharmaceuticals Gmbh Tubulin inhibitors
EP2409983A1 (en) 2010-07-19 2012-01-25 Leibniz-Institut für Pflanzenbiochemie (IPB) Tubulysin analogues
AU2015243379B2 (en) 2014-04-11 2018-02-01 Medimmune Llc Tubulysin derivatives

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005327A1 (de) * 2002-07-09 2004-01-15 Morphochem Ag Komb Chemie Neue tubulysinanaloga
US20050249740A1 (en) * 2002-07-09 2005-11-10 R & D Biopharmaceuticals Gmbh Tubulysin conjugates
US20100240701A1 (en) * 2007-10-25 2010-09-23 Endocyte, Inc. Tubulysins and processes for preparing
WO2010034724A1 (en) * 2008-09-25 2010-04-01 Universität des Saarlandes Bioactive pre-tubulysins and use thereof
CN102725001A (zh) * 2009-08-03 2012-10-10 米德列斯公司 抗增殖化合物、其缀合物、其方法及其用途
WO2011069116A1 (en) * 2009-12-04 2011-06-09 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US20130137139A1 (en) * 2010-08-06 2013-05-30 Endocyte, Inc. Processes for preparing tubulysins
CN103140227A (zh) * 2010-08-06 2013-06-05 恩多塞特公司 制备微管蛋白细胞溶素的方法
WO2013149185A1 (en) * 2012-03-29 2013-10-03 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US20140227295A1 (en) * 2013-02-14 2014-08-14 Bristol-Myers Squibb Company Tubulysin compounds, methods of making and use
CN105073139A (zh) * 2013-02-14 2015-11-18 百时美施贵宝公司 妥布赖森化合物、制备和使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDREW W. PATTERSON ET AL: ""Expedient Synthesis of N-Methyl Tubulysin Analogues with High"", 《JOURNAL OF ORGANIC CHEMISTRY》 *
WANG ZHIYONG ET AL: ""Structure–activity and High-content Imaging"", 《CHEMICAL BIOLOGY & DRUG DESIGN 》 *

Also Published As

Publication number Publication date
EP3261443B1 (en) 2021-04-28
US20180127463A1 (en) 2018-05-10
PE20180355A1 (es) 2018-02-21
PH12017501539A1 (en) 2018-02-05
EA201791896A1 (ru) 2018-02-28
ECSP17057131A (es) 2019-03-29
EP3261443A4 (en) 2018-09-26
AU2016222575A1 (en) 2017-09-07
CA2977589A1 (en) 2016-09-01
MX2017011024A (es) 2017-10-20
JP2018509404A (ja) 2018-04-05
SG11201706820RA (en) 2017-09-28
EP3261443A1 (en) 2018-01-03
HK1248069A1 (zh) 2018-10-12
WO2016138288A1 (en) 2016-09-01
KR20170137725A (ko) 2017-12-13
CO2017008600A2 (es) 2018-02-09
DOP2017000202A (es) 2017-09-29
GT201700190A (es) 2018-11-26
US10808007B2 (en) 2020-10-20
IL254089A0 (en) 2017-10-31
CR20170438A (es) 2018-01-30
CL2017002170A1 (es) 2018-06-08
BR112017018305A2 (pt) 2018-04-17

Similar Documents

Publication Publication Date Title
CN107529754A (zh) 去乙酰氧基微管溶素h及其类似物
CN112118845B (zh) Mcl-1抑制剂
CN108271371B (zh) 用于抑制精氨酸酶活性的组合物和方法
CN111032672B (zh) 作为抗癌剂的环二核苷酸
US20250197379A1 (en) Novel ras inhibitors
RU2618523C2 (ru) Аналоги сплицеостатина
TWI713847B (zh) 治療活性組合物及其使用方法
CN111406063B (zh) 作为抗癌剂的环二核苷酸
RS65100B1 (sr) Selektivni inhibitori nlrp3 inflamazoma
CN111051328A (zh) 作为抗癌剂的环二核苷酸
AU2019204034A1 (en) Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
TW202019406A (zh) 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
CN108430996A (zh) 埃博霉素类似物、合成方法、治疗方法及其药物缀合物
WO2019074824A1 (en) INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
CN112955439A (zh) 用于治疗病理状况的芳族分子
US11274124B2 (en) Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith
CN104203922A (zh) 螺乙内酰脲化合物及其作为选择性雄激素受体调节剂的用途
CN108348489A (zh) Shishijimicin a及其类似物的全合成
US12415789B2 (en) Macrocycles comprising a 4-amido-2,4-pentadienoate moiety for the treatment of hypoxic cancers
HK40104086A (zh) Mcl-1抑制剂
HK40047161B (zh) 取代的四氢环戊二烯并[c]吡咯、取代的二氢吡咯嗪、其类似物和其使用方法
CN110944664A (zh) 含埃博霉素类似物的氮丙啶、合成方法、治疗方法和药物偶联物
HK1235058B (zh) 治疗活性化合物及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180102

WD01 Invention patent application deemed withdrawn after publication